The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Covid-19 Long-Haul
Eligibility Criteria
Inclusion Criteria:
- Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list
Exclusion Criteria:
- History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.
Sites / Locations
- University of California Irvine Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm A
Arm B
Subjects randomized into Group A will take the following amount for 28 days 4 capsules of NAC (600mg each) once in the morning and once in the evening 1 tablet (600mg) of Alamax CR once in the morning and once in the evening 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening
Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days. 4 capsules of NAC (600mg each) once in the morning and once in the evening 1 tablet (600mg) of Alamax CR once in the morning and once in the evening 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening